{"id":"quadrivalent-vlp-vaccine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3322004","moleculeType":"Protein","molecularWeight":"327.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine uses virus-like particles (VLPs) to stimulate the body's immune system, producing antibodies that can recognize and neutralize the influenza virus. This provides protection against infection and reduces the severity of symptoms if the virus is contracted.","oneSentence":"This quadrivalent VLP vaccine induces an immune response against four different strains of the influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:53.844Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT03728881","phase":"PHASE3","title":"Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":1240},{"nctId":"NCT00092534","phase":"PHASE3","title":"Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-14","conditions":"Cervical Cancer, Genital Warts","enrollment":12167},{"nctId":"NCT05329961","phase":"EARLY_PHASE1","title":"Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Medical Center","startDate":"2022-09-26","conditions":"Human Papilloma Virus","enrollment":155},{"nctId":"NCT06915779","phase":"","title":"Long Term Follow-up of HPV Vaccine in HIV (CTN 236)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-06-01","conditions":"Cervical Cancer, Human Papillomavirus Infection, Human Immunodeficiency Virus","enrollment":241},{"nctId":"NCT02653118","phase":"","title":"Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-22","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":4453},{"nctId":"NCT04590521","phase":"PHASE4","title":"HPV Vaccine Immunity in High-risk Women","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-09-14","conditions":"HPV Infection","enrollment":63},{"nctId":"NCT03301051","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2017-08-31","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":10160},{"nctId":"NCT03321968","phase":"PHASE3","title":"Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2017-09-29","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Infections","enrollment":1202},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT03739112","phase":"PHASE3","title":"Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly","status":"COMPLETED","sponsor":"Medicago","startDate":"2018-09-18","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":12794},{"nctId":"NCT00380367","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05-03","conditions":"Papillomavirus Infections","enrollment":110},{"nctId":"NCT03998254","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-26","conditions":"Papillomavirus Infections","enrollment":6000},{"nctId":"NCT00339040","phase":"PHASE2","title":"Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"HIV Infections, Sexually Transmitted Diseases","enrollment":130},{"nctId":"NCT04920526","phase":"","title":"Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls","status":"UNKNOWN","sponsor":"Kenya Medical Research Institute","startDate":"2021-08","conditions":"HPV-Related Carcinoma","enrollment":135},{"nctId":"NCT04711265","phase":"","title":"Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2015-09","conditions":"HPV Vaccine, HPV Infection, HIV-1-infection","enrollment":176},{"nctId":"NCT01101750","phase":"PHASE4","title":"Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2010-05","conditions":"Cervical Cancer, Hpv, Warts","enrollment":25},{"nctId":"NCT03105856","phase":"PHASE4","title":"FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2017-01-03","conditions":"Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma","enrollment":3000},{"nctId":"NCT01991587","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2013-10-08","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":120},{"nctId":"NCT02768805","phase":"PHASE2","title":"Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-03-02","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":900},{"nctId":"NCT00423046","phase":"PHASE3","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-24","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":1106},{"nctId":"NCT02576054","phase":"PHASE3","title":"Safety and Tolerability Study of V501 in Japanese Boys (V501-200)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-20","conditions":"Anogenital Human Papilloma Virus Infection, Condyloma Acuminata","enrollment":101},{"nctId":"NCT02233816","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2014-07-28","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":300},{"nctId":"NCT02236052","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population","status":"COMPLETED","sponsor":"Medicago","startDate":"2014-07-16","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":450},{"nctId":"NCT02831751","phase":"PHASE2","title":"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-04","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":1001},{"nctId":"NCT01862874","phase":"PHASE3","title":"Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-27","conditions":"Anogenital Human Papilloma Virus Infection, Condyloma Acuminata","enrollment":1124},{"nctId":"NCT00834106","phase":"PHASE3","title":"Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-31","conditions":"HPV Infections","enrollment":3006},{"nctId":"NCT01304498","phase":"PHASE3","title":"Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-23","conditions":"Human Papillomavirus","enrollment":600},{"nctId":"NCT01544478","phase":"PHASE4","title":"V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-25","conditions":"Cervical Cancer, Cervical Intraepithelial Neoplasia, Adenocarcinoma in Situ","enrollment":1030},{"nctId":"NCT00543543","phase":"PHASE3","title":"Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-24","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":14840},{"nctId":"NCT02114385","phase":"PHASE3","title":"A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-24","conditions":"Papilloma Viral Infection","enrollment":500},{"nctId":"NCT00092547","phase":"PHASE3","title":"A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-10-08","conditions":"Human, Papillomavirus Infections","enrollment":1781},{"nctId":"NCT00411749","phase":"PHASE2","title":"V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-11","conditions":"HPV Infections","enrollment":107},{"nctId":"NCT00496626","phase":"PHASE3","title":"An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-20","conditions":"Papillomavirus Infections","enrollment":600},{"nctId":"NCT00517309","phase":"PHASE3","title":"Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-12-28","conditions":"Cervical Cancer, Genital Warts","enrollment":1877},{"nctId":"NCT00092482","phase":"PHASE3","title":"Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-28","conditions":"Cervical Cancer, Genital Warts","enrollment":3882},{"nctId":"NCT00337428","phase":"PHASE3","title":"Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus","enrollment":843},{"nctId":"NCT02307851","phase":"PHASE2","title":"Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2014-11","conditions":"Influenza","enrollment":400},{"nctId":"NCT00851643","phase":"PHASE1","title":"Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-04","conditions":"Human Papilloma Virus, Cervical Cancer, Vulvar Cancer","enrollment":158},{"nctId":"NCT00520598","phase":"PHASE2","title":"Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":511},{"nctId":"NCT00365378","phase":"PHASE2","title":"Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-09","conditions":"HPV 16 Infection","enrollment":2409},{"nctId":"NCT00635830","phase":"PHASE1","title":"An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"HPV Infections","enrollment":40},{"nctId":"NCT00365716","phase":"PHASE2","title":"Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-05","conditions":"Papillomavirus Infections, Genital Diseases, Female","enrollment":1158},{"nctId":"NCT00551187","phase":"PHASE2","title":"A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":620},{"nctId":"NCT00092495","phase":"PHASE3","title":"Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-12","conditions":"Cervical Cancer, Genital Warts","enrollment":3055},{"nctId":"NCT01561768","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-03","conditions":"Influenza","enrollment":500},{"nctId":"NCT01427777","phase":"","title":"3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China","status":"UNKNOWN","sponsor":"Guangxi Center for Disease Control and Prevention","startDate":"2011-09","conditions":"Anogenital Human Papilloma Virus Infection","enrollment":300},{"nctId":"NCT00727636","phase":"NA","title":"Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2008-07","conditions":"Inflammatory Bowel Disease","enrollment":53},{"nctId":"NCT01021904","phase":"PHASE4","title":"Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2010-06","conditions":"HPV Infections, Precancerous Disease of the Cervix, Cervical Cancer","enrollment":6200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Quadrivalent VLP Vaccine","genericName":"Quadrivalent VLP Vaccine","companyName":"Medicago","companyId":"medicago","modality":"Biologic","firstApprovalDate":"","aiSummary":"This quadrivalent VLP vaccine induces an immune response against four different strains of the influenza virus. Used for Influenza prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}